Increasing Venture Capital in Kansas
This venture capital funding addresses an immediate need for bioscience businesses in the state and will stimulate the quantity and quality of bioscience venture capital under management in the Kansas region. The funding is designed to:
- Generate superior, risk-adjusted returns for the capital being committed by the KBA;
- Increase the likelihood that high growth potential bioscience companies in Kansas access growth capital to gain full scale commercialization;
- Encourage the development and growth of a vibrant Kansas-based private equity community; and
- Enhance the visibility of Kansas and, specifically, bioscience in Kansas, as a market for attractive venture capital opportunities.
Innovators across Kansas are developing world-class bioscience products and services only to see their true societal and economic development potential suffer for a lack of early stage capital. With the KBA’s venture capital commitment, Kansas is attracting the attention of some of the most respected private venture capital firms in the country to help high growth potential bioscience companies in Kansas access growth capital to gain full-scale commercialization.
And because the eight fund managers must each raise a minimum of $25 million from private and institutional sources, the KBA’s investment will be effectively leveraged to $250 million.
The funds will work closely with the KBA’s Heartland BioVentures initiative, which provides hands-on business assistance and financial resources to high potential early stage bioscience companies to help better position them to raise private growth capital to bring globally competitive products and services to market.
To learn more, please contact the KBA’s Heartland BioVentures president, David Vranicar.
To see what entrepreneurs and venture capital experts are saying about the KBA’s bold venture capital strategy, click here.
For additional background, click here.